EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review



Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review



Journal of Thrombosis and Haemostasis 8(6): 1256-1265



Different rates of inhibitor development after either plasma-derived (pdFVIII) or recombinant (rFVIII) FVIII have been suggested. However, conflicting results are reported in the literature. To systematically review the incidence rates of inhibitor development in previously untreated patients (PUPs) with hemophilia A treated with either pdFVIII or rFVIII and to explore the influence of both study and patient characteristics. Summary incidence rates (95% confidence interval) from all included studies for both pdFVIII and rFVIII results were recalculated and pooled. Sensitivity analysis was used to investigate the effect of study design, severity of disease and inhibitor characteristics. Meta-regression and analysis-of-variance were used to investigate the effect of covariates (testing frequency, follow-up duration and intensity of treatment). Two thousand and ninety-four patients (1965 treated with pdFVIII, 887 with rFVIII; median age, 9.6 months) from 24 studies were investigated and 420 patients were observed to develop inhibitors. Pooled incidence rate was 14.3% (10.4-19.4) for pdFVIII and 27.4% (23.6-31.5) for rFVIII; high responding inhibitor incidence rate was 9.3% (6.2-13.7) for pdFVIII and 17.4% (14.2-21.2) for rFVIII. In the multi-way anova study design, study period, testing frequency and median follow-up explained most of the variability, while the source of concentrate lost statistical significance. It was not possible to analyse the effect of intensity of treatment or trigger events such as surgery, and to completely exclude multiple reports of the same patient or changes of concentrate. These findings underscore the need for randomized controlled trials to address whether or not the risk of inhibitor in PUPs with hemophilia A differs between rFVIII and pdFVIII.

(PDF emailed within 0-6 h: $19.90)

Accession: 055372044

Download citation: RISBibTeXText

PMID: 20345722

DOI: 10.1111/j.1538-7836.2010.03823.x



Related references

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Critical Reviews in Oncology/Hematology 81(1): 82-93, 2012

Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?. Seminars in Thrombosis and Hemostasis 40(2): 269-270, 2014

Initial studies of genetic factors influencing inhibitor development in previously untreated patients with hemophilia treated with recombinant factor VIII. Blood 86(10 SUPPL 1): 610A, 1995

Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thrombosis and Haemostasis 71(5): 544-547, 1994

Cost analysis of plasma-derived factor VIII/von Willebrand factor vs recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics: 1-16, 2018

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109(11): 4693-4697, 2007

First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Seminars in Thrombosis and Hemostasis 28(3): 273-276, 2002

Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Seminars in Thrombosis and Hemostasis 39(7): 752-766, 2014

Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (RecombinateTM). Thrombosis and Haemostasis 83(6): 844-848, 2000

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 98(13): 3600-3606, 2001

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 100(12): 4242; Author Reply 4242-3, 2002

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. New England Journal of Medicine 328(7): 453-459, 1993

Pharmacokinetic analysis of plasma-derived and recombinant factor IX concentrates in previously treated patients with moderate or severe hemophilia B. Annals of Hematology 80(Supplement 1): A16, 2001

Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. International Journal of Hematology 62(1): 35-43, 1995

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 124(23): 3398-3408, 2015